Eraxis (anidulafungin)

No dosing information is available for this tab.

Anidulafungin is administered by slow IV infusion. The drug should not be given by rapid IV injection.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

Anidulafungin is contraindicated in patients with known hypersensitivity to the drug, other echinocandin antifungals (e.g., caspofungin, micafungin), or any ingredient in the formulation.

There are no contraindication contraindications for this drug.

• Pregnancy

There are no moderate contraindications for this drug.

Adverse effects reported in 5% or more of patients receiving anidulafungin include GI effects (nausea , diarrhea, vomiting , dyspepsia ), phlebitis/thrombophlebitis, hypokalemia, increased ALT, increased alkaline phosphatase, increased gamma-glutamyltransferase (GGT, gamma-glutamyl transpeptidase, GGPT), pyrexia, headache, rash, insomnia, anemia, and neutropenia.

More Frequent

• Hypokalemia

Less Frequent

• Deep venous thrombosis
• Hyperglycemia
• Hyperkalemia
• Hypertension
• Hypoglycemic disorder
• Hypomagnesemia
• Hypotension
• Skin rash
• Thrombocytosis

Rare or Very Rare

• Abnormal hepatic function tests
• Anaphylaxis
• Anemia
• Angioedema
• Atrial fibrillation
• Bronchospastic pulmonary disease
• Bundle branch block
• Cholestasis
• Dyspnea
• Erythema
• Hepatic necrosis
• Hepatitis
• Increased risk of bleeding due to coagulation disorder
• Leukocytosis
• Leukopenia
• Pruritus of skin
• Seizure disorder
• Shock
• Sinus node dysfunction
• Thrombocytopenic disorder
• Thrombophlebitis
• Urticaria
• Ventricular premature beats

More Frequent

• Diarrhea
• Fever
• Headache disorder
• Nausea

Less Frequent

• Acute abdominal pain
• Constipation
• Dehydration
• Dyspepsia
• Non-cardiac chest pain
• Peripheral edema

Rare or Very Rare

• Acute cognitive impairment
• Agitation
• Back pain
• Blurred vision
• Chills
• Cough
• Depression
• Dizziness
• Flushing
• Hemoptysis
• Hyperhidrosis
• Insomnia
• Ocular pain
• Pain in extremities
• Visual changes
• Vomiting

No enhanced messaging available.

Safety and efficacy of anidulafungin have not been established in pediatric patients 16 years of age or younger.

Anidulafungin has been used in a limited number of neutropenic children 2-17 years of age+ without unusual adverse effects.

Although data are limited, some experts state that anidulafungin can be considered for first-line treatment of invasive candidiasis or for alternative treatment of esophageal candidiasis in children 2-17 years of age+ with human immunodeficiency virus (HIV) infection.

Category B. (See Users Guide.)

There are no adequate and well-controlled studies of anidulafungin in pregnant women, and the manufacturer states that the drug should be used during pregnancy only if clearly needed.

In rats, anidulafungin crosses the placenta, is detected in fetal plasma, and has been associated with incomplete ossification of several bones.

Anidulafungin is distributed into milk in rats; it is not known whether the drug is distributed into milk in humans.

Anidulafungin should be used with caution in nursing women.

Dosage adjustments are not necessary in patients 65 years of age or older.

Of the total number of patients treated with anidulafungin in clinical trials, 35% were 65 years of age or older and 18% were 75 years of age and older. Although no overall differences in safety and efficacy were observed between geriatric adults 65 years of age or older and younger adults in clinical trials and other clinical experience has not revealed any evidence of age-related differences, the possibility that some older patients may have increased sensitivity to the drug cannot be ruled out.

Dosage adjustments are not necessary when anidulafungin is used in geriatric patients.